Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 105,250,712
  • Shares Outstanding, K 1,639,930
  • Annual Sales, $ 19,427 M
  • Annual Income, $ 4,457 M
  • 36-Month Beta 1.19
  • Price/Sales 5.37
  • Price/Cash Flow 20.73
  • Price/Book 7.04

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.57 +1.81%
on 09/27/17
66.10 -3.63%
on 10/13/17
+1.00 (+1.59%)
since 09/18/17
3-Month
52.06 +22.36%
on 07/27/17
66.10 -3.63%
on 10/13/17
+8.96 (+16.37%)
since 07/18/17
52-Week
46.01 +38.45%
on 01/26/17
66.10 -3.63%
on 10/13/17
+13.65 (+27.27%)
since 10/18/16

Most Recent Stories

More News
What to Expect from Big Pharmas After J&J's Solid Q3 Results?

Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.

JNJ : 140.68 (-0.08%)
MRK : 63.51 (+0.46%)
LLY : 85.73 (-0.38%)
NVS : 86.04 (-0.35%)
PFE : 35.83 (-1.02%)
GSK : 41.01 (+0.44%)
BMY : 63.70 (-0.75%)
Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?

At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.

RHHBY : 31.0100 (-1.40%)
PFE : 35.83 (-1.02%)
BMY : 63.70 (-0.75%)
BIIB : 344.58 (+0.03%)
Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

LLY : 85.73 (-0.38%)
INCY : 115.14 (-0.43%)
PFE : 35.83 (-1.02%)
BMY : 63.70 (-0.75%)
Bristol-Myers Gets Priority Review for Opdivo Label Expansion

Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.

AZN : 34.65 (-0.37%)
NVO : 50.13 (+1.66%)
MRK : 63.51 (+0.46%)
BMY : 63.70 (-0.75%)
FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx

Exelixis (EXEL) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for kidney cancer drug Cabomteyx.

EXEL : 27.53 (-2.72%)
RHHBY : 31.0100 (-1.40%)
GSK : 41.01 (+0.44%)
BMY : 63.70 (-0.75%)
Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious...

CRBP : 7.00 (-0.71%)
DNPUF : 13.6000 (+4.62%)
ARIA : 23.99 (+0.17%)
MRK : 63.51 (+0.46%)
MDCO : 34.54 (-0.09%)
LLY : 85.73 (-0.38%)
MTZPY : 23.0400 (+1.45%)
BMY : 63.70 (-0.75%)
MKKGY : 22.2750 (-0.47%)
Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious...

CRBP : 7.00 (-0.71%)
DNPUF : 13.6000 (+4.62%)
ARIA : 23.99 (+0.17%)
MRK : 63.51 (+0.46%)
MDCO : 34.54 (-0.09%)
LLY : 85.73 (-0.38%)
MTZPY : 23.0400 (+1.45%)
BMY : 63.70 (-0.75%)
MKKGY : 22.2750 (-0.47%)
U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb's Application for Opdivo (nivolumab) in Patients with Resected High-Risk Advanced Melanoma and Grants Priority Review

--Application based on results from Phase 3 CheckMate -238 study

BMY : 63.70 (-0.75%)
5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings

The pharma/biotech sector has a number of things going in its favor.

AZN : 34.65 (-0.37%)
LLY : 85.73 (-0.38%)
PFE : 35.83 (-1.02%)
GSK : 41.01 (+0.44%)
BMY : 63.70 (-0.75%)
Bristol-Myers (BMY), TARGET Extend Partnership for NASH Study

Bristol-Myers Squibb (BMY) extended its strategic partnership with TARGET PharmaSolutions, Inc. for NASH study.

NVS : 86.04 (-0.35%)
GILD : 80.01 (-0.29%)
ICPT : 66.53 (-0.79%)
BMY : 63.70 (-0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain;...

See More

Support & Resistance

2nd Resistance Point 65.13
1st Resistance Point 64.42
Last Price 63.70
1st Support Level 63.27
2nd Support Level 62.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart